Compare McKesson Corporation (MCK) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs SOLAI Limited — how do they compare? McKesson Corporation trades at $892.91 (market cap $105.14B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: McKesson Corporation is far larger — about 6299.6× SOLAI Limited's market cap, and McKesson Corporation pays a 0.42% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| MCK | SLAI | |
|---|---|---|
Market Cap | $105.14B | $16.69M |
Sector | Health | Technology |
52-Week High | $995.69 | $26.74 |
52-Week Low | $659.01 | $2.74 |
Enterprise Value | $111.67B | $16.33M |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $879.87, up 1.18% today, with strong momentum from recent earnings beats and raised guidance. The stock shows bullish technical signals, supported by robust revenue growth and solid cash flow generation. Recent news highlights strength in specialty drugs and oncology, driving positive sentiment.
Outlook remains favorable with a consensus price target of $990.67, though thin profit margins and high liabilities pose risks. Continued execution on growth initiatives and cost discipline are key for sustained upside, while macroeconomic pressures and competitive dynamics require monitoring.
SLAI trades at $3.72 with no recent price movement. The company faces severe financial distress with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Technical indicators show a bullish signal despite fundamental weakness. Recent developments include a 7:1 reverse stock split effective July 2026 and NYSE delisting proceedings initiated in July 2026 following multiple compliance notices.
Investment outlook remains highly speculative given the company's financial deterioration and exchange delisting risk. The acquisition of NEURALAND stake and Solode Neo product launch provide potential growth catalysts, but current negative profitability and cash flow challenges outweigh near-term opportunities. Analyst consensus shows 100% hold rating with no buy recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
